Based on the Sonnet Biotherapeutics Holdings Inc stock forecast from 0 analysts, the average analyst target price for Sonnet Biotherapeutics Holdings Inc is not available over the next 12 months. Sonnet Biotherapeutics Holdings Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Sonnet Biotherapeutics Holdings Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Sonnet Biotherapeutics Holdings Inc’s stock price was USD 1.23. Sonnet Biotherapeutics Holdings Inc’s stock price has changed by -4.65% over the past week, -3.91% over the past month and -98.93% over the last year.
No recent analyst target price found for Sonnet Biotherapeutics Holdings Inc
No recent average analyst rating found for Sonnet Biotherapeutics Holdings Inc
Company Overview Sonnet Biotherapeutics Holdings Inc
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. Read Less
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hike...Read More
Frequently Asked Questions About Sonnet Biotherapeutics Holdings Inc (SONN) Stock
Stock Target Advisor's fundamental analysis for Sonnet Biotherapeutics Holdings Inc's stock is Bearish.
Unfortunately we do not have enough data on SONN's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SONN's stock to indicate what its average analyst target is.
SONN stock's Price/Earning ratio is 0.26.
Our analysis grades SONN stock's Price / Earning ratio at B-. This means that SONN stock's Price/Earning ratio is above 18.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SONN may be undervalued for its sector.
The last closing price of SONN's stock was USD 1.23.
The most recent market capitalization for SONN is USD 3.95M.
Unfortunately we do not have enough analyst data on SONN's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Sonnet Biotherapeutics Holdings Inc's stock.
As per our most recent records Sonnet Biotherapeutics Holdings Inc has 13 Employees.
Sonnet Biotherapeutics Holdings Inc's registered address is 100 Overlook Center, Princeton, NJ, United States, 08540.
You can get more information about it from Sonnet Biotherapeutics Holdings Inc's website at https://www.sonnetbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Sonnet Biotherapeutics Holdings Inc (SONN) Stock
Stock Target Advisor's fundamental analysis for Sonnet Biotherapeutics Holdings Inc's stock is Bearish.
Unfortunately we do not have enough data on SONN's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SONN's stock to indicate what its average analyst target is.
SONN stock's Price/Earning ratio is 0.26.
Our analysis grades SONN stock's Price / Earning ratio at B-. This means that SONN stock's Price/Earning ratio is above 18.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SONN may be undervalued for its sector.
The last closing price of SONN's stock was USD 1.23.
The most recent market capitalization for SONN is USD 3.95M.
Unfortunately we do not have enough analyst data on SONN's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Sonnet Biotherapeutics Holdings Inc's stock.
As per our most recent records Sonnet Biotherapeutics Holdings Inc has 13 Employees.
Sonnet Biotherapeutics Holdings Inc's registered address is 100 Overlook Center, Princeton, NJ, United States, 08540.
You can get more information about it from Sonnet Biotherapeutics Holdings Inc's website at https://www.sonnetbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SONN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
